These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 9459344

  • 21. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.
    Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ.
    J Clin Pharmacol; 2002 Dec; 42(12):1326-34. PubMed ID: 12463727
    [Abstract] [Full Text] [Related]

  • 22. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760.
    Nichols AJ, Vasko JA, Koster PF, Valocik RE, Rhodes GR, Miller-Stein C, Boppana V, Samanen JM.
    J Pharmacol Exp Ther; 1994 Aug; 270(2):614-21. PubMed ID: 8071853
    [Abstract] [Full Text] [Related]

  • 23. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [Abstract] [Full Text] [Related]

  • 24. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.
    Herbert JM, Savi P, Jeske WP, Walenga JM.
    Thromb Haemost; 1998 Aug; 80(2):326-31. PubMed ID: 9716161
    [Abstract] [Full Text] [Related]

  • 25. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL, Malinin AI, O'connor CM, Gurbel PA, Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy.
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [Abstract] [Full Text] [Related]

  • 26. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs.
    Prueksaritanont T, Gorham LM, Yeh KC.
    J Pharm Sci; 1997 Dec; 86(12):1345-51. PubMed ID: 9423143
    [Abstract] [Full Text] [Related]

  • 27. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S.
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin.
    Reimann JD, Modi NB, Novotny W.
    J Clin Pharmacol; 2000 May; 40(5):488-95. PubMed ID: 10806602
    [Abstract] [Full Text] [Related]

  • 29. UR-3216: a new generation oral platelet GPIIb/IIIa antagonist.
    Aga Y, Baba K, Tam S, Nakanishi T, Yoneda K, Kita J, Ueno H.
    Curr Pharm Des; 2004 May; 10(14):1597-601. PubMed ID: 15134558
    [Abstract] [Full Text] [Related]

  • 30. Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734,217, in dogs.
    Prueksaritanont T, Stranieri MT, Hand EL, Ellis JD, Holahan MA, Sitko GR, Cook JJ.
    Biopharm Drug Dispos; 1997 Nov; 18(8):649-63. PubMed ID: 9373723
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
    Mutlib AE, Diamond S, Shockcor J, Way R, Nemeth G, Gan L, Christ DD.
    Xenobiotica; 2000 Nov; 30(11):1091-110. PubMed ID: 11197070
    [Abstract] [Full Text] [Related]

  • 33. Absorption of lefradafiban from different sites of the gastrointestinal tract.
    Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C.
    Br J Clin Pharmacol; 2000 Jul; 50(1):69-72. PubMed ID: 10886122
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys.
    Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF.
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2877-82. PubMed ID: 17562805
    [Abstract] [Full Text] [Related]

  • 35. Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
    Beconi MG, Yates D, Lyons K, Matthews K, Clifton S, Mead T, Prime M, Winkler D, O'Connell C, Walter D, Toledo-Sherman L, Munoz-Sanjuan I, Dominguez C.
    Drug Metab Dispos; 2012 Dec; 40(12):2297-306. PubMed ID: 22942319
    [Abstract] [Full Text] [Related]

  • 36. Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.
    Thuita JK, Wolf KK, Murilla GA, Liu Q, Mutuku JN, Chen Y, Bridges AS, Mdachi RE, Ismail MA, Ching S, Boykin DW, Hall JE, Tidwell RR, Paine MF, Brun R, Wang MZ.
    PLoS Negl Trop Dis; 2013 Dec; 7(6):e2230. PubMed ID: 23755309
    [Abstract] [Full Text] [Related]

  • 37. Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients.
    De Deyn PP, Van de Velde V, Verslegers W, Saerens J, Pickut BA, Clincke B, Woestenborghs R, Van Peer A.
    Eur J Clin Pharmacol; 1992 Dec; 43(6):661-2. PubMed ID: 1493851
    [Abstract] [Full Text] [Related]

  • 38. Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981.
    Yellepeddi VK, Zhudeva MY, Movahedi F, Vo A, Phan J, Kirsh RD, Rawlins DB, Talbot JN.
    J Pharm Sci; 2018 Sep; 107(9):2472-2478. PubMed ID: 29800545
    [Abstract] [Full Text] [Related]

  • 39. Sibrafiban.
    Dooley M, Goa KL.
    Drugs; 1999 Feb; 57(2):225-30; discussion 231-2. PubMed ID: 10188763
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
    Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, Blackburn B, Beresini M, Weller T, Steiner B, Bunting S.
    Thromb Haemost; 1998 Jan; 79(1):169-76. PubMed ID: 9459344
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.